Cell Therapy Technologies Market Size, Share, Growth Analysis, By Technology(Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology), By Use(Clinical Use), By Cell(Stem Cell Therapies, BM, Blood, & Umbilical Cord-derived Stem Cells), By Therapy(Allogenic Therapies, Autologous Therapies), By Product(Consumables, Equipment, Systems, and Software), By Therapeutic Area(Oncology, Musculoskeletal Diseases), By Region - Industry Forecast 2024-2031

Drivers

Development of Novel Therapies

• The market growth is also supported by the constant introduction of new technologies to enable cutting-edge therapies. The introduction of proprietary cells is generally considered to be the most efficient way to obtain a large population of targets for a single product. For example, Immunicum is using Chimeric Antigen Receptor T cell (CAR-T) growth, dendritic cell neoantigen presentation technology, and T-cell primers to improve its immuno-oncology product development.

Rise of Generalized Medicine

• The rise of generalized medicine has raised the level of medical education. Cell therapy, particularly involving engineered cells, enables the development of customized therapies targeting the unique genotypes of individual patients. This personalized testing greatly improves the efficacy of treatment and reduces adverse effects, marking a paradigm shift in the way health care is delivered. Stem cell therapy is also gaining more attention due to its use in therapies for autoimmune and metabolic disorders. It plays a vital role in a person’s immune response to a variety of metabolites. For example, in May 2022, Cernova and Evotec collaborated to develop cell therapies for use in insulin-dependent diabetes using induced pluripotent stem cell (iPSC)-based therapies.

Restraints

• Lack of Skilled Labor to Create Market Challenges

Despite technological advances and inventions over the past decade, there is a lack of skilled personnel to operate complex instruments such as flow cytometers and a lack of many readers. Flow cytometers and spectrophotometers, which are technologically advanced and extremely robust, generate large amounts of data that require skill to analyze and review.

• Regulatory Hurdles

Manufacturing complexity, including cell expansion, differentiation, and purification, presents challenges in large-scale manufacturing, resulting in higher costs, longer lead times, and changes in production. Strict regulatory requirements in cell therapy, including safety, efficacy, and quality standards, lead to timeline delays, and cost savings in bringing therapies to market are high, limiting smaller companies with limited resources.